← All indications
Thyroid Neoplasms
Tumors or cancer of the THYROID GLAND.
Subtype terms (2)
More specific conditions that are subtypes of Thyroid Neoplasms in the MeSH hierarchy.
- Thyroid Cancer, Papillary
34 drugs (23 approved, 11 experimental)
- Thyroid Nodule
21 drugs (17 approved, 4 experimental)
Drugs by status
Approved for this indication (14)
Phase 4 trials (23)
Phase 3 trials (10)
Phase 2 trials (133)
- decitabine
- vitamin d3
- denosumab
- gallium-68-dotatate
- Ga 68 PSMA-11
- abemaciclib
- radium-223
- afatinib
- axitinib
- aldoxorubicin
- atezolizumab
- tf2
- autologous tumor infiltrating lymphocytes
- avelumab
- mk-1775
- azd-4547
- barium sulphate
- binimetinib
- carum cravi
- lenalidomide
- temsirolimus
- ceritinib
- cobimetinib
- pancrelipase
- cudc-907
- valproic acid
- dovitinib
- doxorubicin
- durvalumab
- efatutazone
- +103 more
Phase 1 trials (55)
- 177lu-pp-f11n
- azacitidine
- brodalumab
- mkc1106
- blu-667
- cixutumumab
- photochlor
- 13c-pyruvate
- ktn3379
- mgd009
- octreotide
- trastuzumab
- prostate specific membrane antigen
- methylene blue
- fowlpox-sargramostim
- recombinant fowlpox-cea(6d)/tricom vaccine
- interleukin-12
- hyaluronic acid
- sitagliptin
- temozolomide
- gelofusin
- cetuximab
- bexarotene
- thyrotropin releasing hormone
- cellulose
- veliparib
- vinorelbine
- cbt-101
- taest16001
- erlotinib
- +25 more
Other trials (35)
- propofol
- 99mtc mdp
- 18f-6-l-fluorodihydroxyphenylalanine
- calcium carbonate
- bvd-523
- sevoflurane
- i-124
- magnesium oxide
- whey protein
- alendronic acid
- magnesium sulfate
- remimazolam
- rocuronium
- levobupivacaine
- desflurane
- digoxin
- ferumoxytol
- gefitinib
- ondansetron
- coffee
- cu 64 m5a
- dexmedetomidine
- multivitamins
- tea
- aprepitant
- doxepin
- remifentanil
- ergocalciferol
- tetrafluoroborate
- f-18-psma-1007
- +5 more
Organizations
Organization Involved with Phase 4 Indications (17)
- Genzyme
- Sanofi
- Shenzhen SiBiono GeneTech Co.,Ltd
- National Cancer Institute, France
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Doctors Hospital at Renaissance
- Sichuan University
- University of Southern Denmark
- University of Toronto
- Yonsei University
- University of Copenhagen
- Shandong Province Qianfoshan Hospital
- Saint-Petersburg State Medical University
- Akrimax Pharmaceuticals
- Government of Brazil
- The University of Texas, Dallas
- Shandong first medical University
Organization Involved with Phase 3 Indications (21)
- Amgen
- Eli Lilly
- Bayer
- Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
- Mateon Therapeutics
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- National Cancer Center, Korea
- University of Pennsylvania
- Cancer Research UK
- University of London
- Cornell University
- Newcastle University
- Seoul National University
- University of Milan
- Yale University
- Vancouver Coastal Health
- Tsinghua University
- Loxo Oncology
- Institut Gustave Roussy
- Sungkyunkwan University
- Chinese Academy of Medical Sciences
Organization Involved with Phase 2 Indications (89)
- Daiichi Sankyo
- Celgene
- Millennium Pharmaceuticals
- Bristol-Myers Squibb
- Genmab
- Roche
- Immunomedics
- Merck
- Genentech
- Merck KGaA
- Plexxikon
- Pfizer
- Novartis
- GlaxoSmithKline
- Ignyta, Inc.
- Kura Oncology, Inc.
- NantCell, Inc.
- Salient Pharmaceuticals Incorporated
- Eanm Research Ltd
- Stemcentrx
- Turning Point Therapeutics
- National Institutes of Health (NIH)
- National Cancer Institute (NCI)
- Region Skane
- Academic and Community Cancer Research United
- Case Western Reserve University
- Centre Leon Berard
- Harvard University
- ECOG-ACRIN Cancer Research Group
- Emory University
- +59 more
Organization Involved with Phase 1 Indications (29)
- BioMed Valley Discoveries, Inc
- Blueprint Medicines Corporation
- Celldex Therapeutics
- Medical University Innsbruck
- Thomas Jefferson University
- University of Groningen
- University of Pisa
- Utrecht University
- University of Bern
- University of Zurich
- University of California, Los Angeles
- University of Colorado, Denver
- Vanderbilt University
- University of Basel
- University of Freiburg
- University of Ljubljana
- State University of New York, Buffalo
- Jagiellonian University
- Erasmus University Rotterdam
- James B. and Lois R. Archer Charitable Foundation
- Gateway for Cancer Research
- American Cancer Society, Inc.
- Krebsforschung Schweiz, Bern, Switzerland
- Alberta Cancer Foundation
- Yeshiva University
- NATIONAL CENTRE FOR NUCLEAR RESEARCH, Poland
- INRASTES, NCSR Demokritos, Athens, Greece
- Paul Scherrer Institute, Villigen, Switzerland
- AffyImmune Therapeutics, Inc.
Organization Involved with Other Experimental Indications (22)
- Ethicon
- Ajou University
- Chulalongkorn University
- Deutsche Krebshilfe e.V.
- Inje University
- Julius-Maximilians University
- Radboud University
- University of South Carolina
- University of Tartu
- Medical University of South Carolina
- Jiao Tong University
- Southern Medical University
- Chosun University
- University of Sao Paulo
- Ewha Womans University
- University of Sherbrooke
- Dutch Cancer Society
- Dongnam Institute of Radiological & Medical Sciences
- Aix-University of Marseille
- Henkel
- Cancer Commons
- xCures